Cargando…

Both Carboplatin and Bevacizumab Improve Pathological Complete Remission Rate in Neoadjuvant Treatment of Triple Negative Breast Cancer: A Meta-Analysis

Triple negative breast cancer (TNBC) is associated with high pathological complete remission (pCR) rate in neoadjuvant treatment (NAT). TNBC patients who achieve pCR have superior outcome than those without pCR. A meta-analysis was done to evaluate whether integrating novel approaches into NAT can i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xiao-song, Yuan, Ying, Garfield, David H., Wu, Jia-yi, Huang, Ou, Shen, Kun-wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172579/ https://www.ncbi.nlm.nih.gov/pubmed/25247558 http://dx.doi.org/10.1371/journal.pone.0108405

Ejemplares similares

Liver Metastasis of a Triple-Negative Breast Cancer and Complete Remission for 5 Years After Treatment With Combined Bevacizumab/Paclitaxel/Carboplatin: Case Report and Review of the Literature
por: Ogata, Hideaki, et al.
Publicado: (2015)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis
por: Vidra, Radu, et al.
Publicado: (2022)

Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis
por: Ma, Xuelei, et al.
Publicado: (2016)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
por: Shepherd, Jonathan H., et al.
Publicado: (2022)

Pathological complete response to neoadjuvant chemotherapy, but not the addition of carboplatin, is associated with improved survival in Chilean triple negative breast cancer patients: a report of real world data
por: Walbaum, Benjamín, et al.
Publicado: (2021)

Insulin-like growth factor-1, metabolic abnormalities, and pathological complete remission rate in HER2-positive breast cancer patients receiving neoadjuvant therapy
por: Tong, Yi-Wei, et al.
Publicado: (2019)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
por: Ji, Jung Hwan, et al.
Publicado: (2022)

Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Nakashoji, Ayako, et al.
Publicado: (2017)

A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer()
por: Wang, Gen, et al.
Publicado: (2017)

Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer
por: Montero, Alberto, et al.
Publicado: (2012)

Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
por: Gass, Paul, et al.
Publicado: (2018)

Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
por: Sivina, Elina, et al.
Publicado: (2023)

Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
por: Ruan, Miao, et al.
Publicado: (2018)

Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer: Time to rethink standard of care?
por: Klavans, Madison R., et al.
Publicado: (2020)

Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2021)

Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Pairwise and Network Meta-Analysis of Pathological Complete Response
por: Weng, Zeng-Jie, et al.
Publicado: (2021)

Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial
por: de Pádua Souza, Cristiano, et al.
Publicado: (2023)

Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles
por: Lee, Sung Hwan, et al.
Publicado: (2015)

Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy
por: Wu, Kunpeng, et al.
Publicado: (2014)

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
por: Wang, Ruo-Xi, et al.
Publicado: (2016)

Association Between Background Parenchymal Enhancement and Pathologic Complete Remission Throughout the Neoadjuvant Chemotherapy in Breast Cancer Patients
por: You, Chao, et al.
Publicado: (2017)

A predictor of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients with the DNA repair genes
por: Huang, Liang, et al.
Publicado: (2021)

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy
por: Toss, Angela, et al.
Publicado: (2022)

A case report of locally advanced triple negative breast cancer showing pathological complete response to weekly paclitaxel with bevacizumab treatment following disease progression during anthracycline-based neoadjuvant chemotherapy
por: Shigematsu, Hideo, et al.
Publicado: (2017)

Prediction of pathologic complete response to neoadjuvant systemic therapy in triple negative breast cancer using deep learning on multiparametric MRI
por: Zhou, Zijian, et al.
Publicado: (2023)

Weekly vs Every-3-Week Carboplatin with Weekly Paclitaxel in Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Retrospective Analysis
por: Landry, Kara K, et al.
Publicado: (2022)

A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013
por: Ademuyiwa, Foluso O., et al.
Publicado: (2022)

The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
por: Cuyàs, Elisabet, et al.
Publicado: (2019)

Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial
por: Zhang, Pin, et al.
Publicado: (2016)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy
por: Li, JunJie, et al.
Publicado: (2016)

A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence
por: Fournier, Marcia V., et al.
Publicado: (2019)

Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy
por: Masuda, Hiroko, et al.
Publicado: (2022)

Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
por: Dieci, Maria Vittoria, et al.
Publicado: (2022)

Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
por: Nakao, Yuri, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_bfmp9h968odmialbikh5oanflh